Evidence map›Paper›PMID 34226698›Full record

ArticleNature cell biology2021

CCM3 is a gatekeeper in focal adhesions regulating mechanotransduction and YAP/TAZ signalling.

Shan Wang, Emelie Englund, Pontus Kjellman, Zhen Li, Johannes Kumra Ahnlide, Carmen Rodriguez-Cupello, Mattia Saggioro, Ryu Kanzaki, Kristian Pietras, David Lindgren and 4 more

RetractedAbstract readRetracted Publication
PubMed Publisher
In one paragraph

Article in Nature cell biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Focus on mechano-immunology: new direction in cancer treatment.International journal of surgery (London, England) · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. The Hippo Pathway in Breast Cancer: The Extracellular Matrix and Hypoxia.International journal of molecular sciences · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Shan WangDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-4798-2983
Emelie EnglundDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0001-7614-421X
Pontus KjellmanDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Zhen LiDivision of Solid State Physics and NanoLund, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-7030-5796
Johannes Kumra AhnlideDivision of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-8136-8928
Carmen Rodriguez-CupelloDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0003-3611-2496
Mattia SaggioroDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-0002-3419
Ryu KanzakiDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-6492-4021
Kristian PietrasDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0001-6738-4705
David LindgrenDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Håkan AxelsonDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-7749-5043
Christelle N PrinzDivision of Solid State Physics and NanoLund, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-1726-3275
Vinay SwaminathanDivision of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-9946-810X
Chris D MadsenDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden. chris.madsen@med.lu.se.ORCID http://orcid.org/0000-0001-6838-2103
Lund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The YAP/TAZ transcriptional programme is not only a well-established driver of cancer progression and metastasis but also an important stimulator of tissue regeneration. Here we identified Cerebral cavernous malformations 3 (CCM3) as a regulator of mechanical cue-driven YAP/TAZ signalling, controlling both tumour progression and stem cell differentiation. We demonstrate that CCM3 localizes to focal adhesion sites in cancer-associated fibroblasts, where it regulates mechanotransduction and YAP/TAZ activation. Mechanistically, CCM3 and focal adhesion kinase (FAK) mutually compete for binding to paxillin to fine-tune FAK/Src/paxillin-driven mechanotransduction and YAP/TAZ activation. In mouse models of breast cancer, specific loss of CCM3 in cancer-associated fibroblasts leads to exacerbated tissue remodelling and force transmission to the matrix, resulting in reciprocal YAP/TAZ activation in the neighbouring tumour cells and dissemination of metastasis to distant organs. Similarly, CCM3 regulates the differentiation of mesenchymal stromal/stem cells. In conclusion, CCM3 is a gatekeeper in focal adhesions that controls mechanotransduction and YAP/TAZ signalling.

Indexed as

Mechanotransduction, CellularAdaptor Proteins, Signal TransducingAnimalsApoptosis Regulatory ProteinsBreast NeoplasmsCancer-Associated FibroblastsCell CommunicationCell DifferentiationCell Line, TumorFemaleFocal Adhesion Kinase 1Focal AdhesionsGene Expression Regulation, NeoplasticHumansIntracellular Signaling Peptides and ProteinsMembrane ProteinsAdaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsFocal Adhesion Kinase 1Intracellular Signaling Peptides and ProteinsMembrane ProteinsPaxillinPDCD10 protein, humanPDCD10 protein, mouseProto-Oncogene ProteinsPTK2 protein, humanPtk2 protein, mousePXN protein, humanPxn protein, mousesrc-Family KinasesTranscriptional Coactivator with PDZ-Binding Motif ProteinsTranscription FactorsWWTR1 protein, humanWwtr1 protein, mouseYAP1 protein, humanYap1 protein, mouseYAP-Signaling Proteins

Identifiers

PMID34226698
OpenAlexW3181673453

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.